Impact of out-stent plaque characteristics on vascular response after second generation drug-eluting stent implantation: iMAP-intravascular ultrasound and angioscopic study

Kenji Kawai a,b, Minoru Ichikawa a, Tohru Masuyama b, Masaharu Ishihara b, Yoshiyuki Kijima a,⁎

a Department of Cardiology, Higashi-osaka City Medical Center, 3-4-5 Nishi Iwata, Higashi-osaka, Osaka 578-8588, Japan
b Division of Cardiovascular Medicine and Coronary Heart Disease, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

A R T I C L E   I N F O
Article history:
Received 27 February 2018
Accepted 13 May 2018
Available online xxxx

Keywords:
Second generation drug-eluting stent
Arterial repair
Plaque characteristics
Intravascular ultrasound
Coronary angioscopy

A B S T R A C T
Purpose: The purpose of this study is to elucidate the impact of out-stent plaque characteristics on vascular response after implantation of second generation drug-eluting stent (G2-DES).

Methods: Enrolled were 37 patients with 39 coronary artery lesions into which three types of G2-DES were successfully implanted (9 Nobori biolimus-, BES; 15 Xience everolimus-, EES; 15 Resolute zotarolimus-eluting stents; R-ZES). Immediately after (baseline) and one year after the implantation (follow-up), iMAP-intravascular ultrasound (IVUS) was performed to measure out-stent plaque volume (OSPV) and its components. Percent OSPV and vulnerable plaque index (VPI) were defined as percente of OSPV to vessel volume and as percente of lipidic plus necrotic volume to OSPV. Coronary angioscopy at follow-up rated the degree of arterial repair by neointimal stent coverage (NSC).

Results: Poor NSC was found in approximately 60% of each G2-DES. In BES, % OSPV at baseline was significantly greater in poor NSC than in good NSC (36.2 ± 3.9 vs. 27.3 ± 4.0%, P = 0.01). In EES, %OSPV was significantly greater in poor NSC than in good NSC (41.0 ± 4.1 vs. 32.6 ± 2.7%, P = 0.01). In R-ZES implantation, there was no significant difference with regards to %OSPV between poor and good NSC. In BES, VPI at baseline was significantly greater in poor NSC than good NSC (54.0 ± 5.8 vs. 42.2 ± 5.1%, P = 0.02). There was no significant difference with regards to VPI between poor and good NSC in EES and R-ZES.

Conclusions: Impact of out-stent plaque characteristics on vascular response was different among the three types of G2-DES.

© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Although arterial repair after intracoronary implantation of drug-eluting stents (DES) depends not only on bio-suppressive drug elution from stent struts but also on solvent polymer [1], impact of out-stent plaque characteristics on arterial repair has been controversial [2]. Pathology revealed the delayed arterial repair after implantation of the first generation drug-eluting stents (G1-DES) in comparison with bare metal stents [3]. This delay was angioscopically characterized by poor neointimal stent coverage (NSC) and in-stent yellow plaque [4,5]. Autopsy revealed that NSC after G1-DES implantation delayed in cadavers with acute myocardial infarction in comparison with those with stable angina pectoris [6]. The delayed arterial repair might cause very late stent thrombosis, a serious complication of DES implantation.

In this study, we performed one-year follow up of arterial repair after implantation of the second generation drug-eluting stents (G2-DES) into patients with coronary artery disease. We employed coronary angioscopy as well as iMAP-intravascular ultrasound (IVUS) to assess plaque characteristics [7]. The purpose of this study was to elucidate the impact of out-stent plaque volume (OSPV) and plaque vulnerability on vascular response after implantation of three types of G2-DES.

2. Methods

2.1. Study population

From July 2012 to July 2013, enrolled were consecutive 40 patients with coronary artery diseases who received successful implantation of G2-DES at their culprit lesions. For this period, we did not fail to implant G2-DES. Implanted stents were composed of Xience everolimus-eluting stents (EES, Xience®, Abbott-vascular Co., Abbott Park, IL, USA), Resolute zotarolimus-eluting stents (R-ZES, Resolute Integrity®, Medtronic Co., Minneapolis, MN, USA), and biolimus-eluting stents (BES, Nobori®, Terumo Co., Tokyo, Japan). Selection of G2-DES depended on operator’s preference. Immediately after the stent implantation, iMAP-IVUS were performed (baseline). When a patient received two stents, we implanted the same G2-DES as the first one. In other words, cases with hybrid stenting (bare-metal stent/DES and different types of G2-DES) were excluded from the enrollment. Dual anti-platelet therapy, 75 mg clopidogrel and 100 mg aspirin, had been continued at least for one year until follow-up coronary angiography (CAG). Two patients were withdrawn from the follow-up because of stroke and non-cardiac death.
Follow-up CAG was performed at one year after the stent implantation, revealing in-stent restenosis in a patient who was withdrawn from further intracoronary imaging analyses. Subsequently, 39 stents in 37 patients, i.e. 18 acute coronary syndrome (ACS) and 19 stable angina pectoris (SAP), were subjected to iMAP-IVUS and coronary angiography (follow-up). The study protocol was approved by our institutional review board. A written informed consent was obtained from each patient before his or her participation.

2.2. iMAP-IVUS analyses

IVUS was performed by iMAP™-system (Boston Scientific Corp, Fremont, CA, USA). A 3.6 Fr 40 MHz IVUS catheter (Atrantis SR Pro 2; Boston Scientific Corporation, Minneapolis, MN) was introduced into a coronary artery. First, gray-scale IVUS provided planimetric data throughout stent length at every 0.5 mm interval. Vessel area was defined as inner area within outer border of sonolucent zone. Vessel volume and stent volume were calculated by integral from distal to proximal edge of each stent (Fig. 1). Out-stent plaque volume (OSPV) was defined as subtraction of stent volume from vessel volume. Percent OSPV (%OSPV), a representative parameter for plaque burden, was calculated as ratio of OSPV to vessel volume.

Second, iMAP system provided the tissue characterization of out-stent plaques [7]. On the cross section images, iMAP coded the out-stent plaques as light-green (fibrotic), yellow (lipidic), pink (necrotic), light-blue (calcified), and artifact area. Artifact area was caused by interference of guide wires (ignored area). Employing EchoPlaque Analysis software (INDEC Medical Systems, Santa Clara, CA), fractions of each component in out-stent plaques were calculated by integral throughout stent length at every 0.5 mm interval (Fig. 1). To assess out-stent plaque vulnerability, we tentatively defined vulnerable plaque index (VPI) as ratio of lipidic plus necrotic volume to total OSPV.

2.3. Coronary angiography

Coronary angiography (Visible™, Fiber-tech, Tokyo) was performed through a 6 Fr sheath under continuous flush of 3% dextran 40 as described previously [8,9]. It visualized in-stent appearance, i.e. grade of neointimal stent coverage (NSC), presence of yellow plaque, and mural thrombus. NSC was classified into two grades, poor or good coverage [10]. Poor NSC was corresponded to grade 0–1, and good NSC was corresponded to grade 2–3 according to previous report methods [2,5]. When both grades were observed in a stent, dominant grade of NSC was assigned to the grade of the entire stented segment. All angioscopic data were evaluated by 2 angioscopic specialists blinded to the patient characteristics.

Fig. 1. A representative case. At baseline (A), EES (dotted line) was successfully implanted into proximal LAD, a culprit lesion of anterior acute myocardial infarction, in a 70-year-old male. At the center of EES (arrowhead), cross sectional images of gray-scale IVUS (a) and iMAP-IVUS (a’) were shown. Planimetry of out-stent plaque was done in the former. The out-stent plaque was colorized on the basis of tissue characteristics (a’). Artifact area caused by guide wire interference was excluded for iMAP analysis (arrow). Integral of each area throughout the stent gave each volume. At follow-up (B), cross sectional images of gray-scale IVUS (b) and iMAP-IVUS (b’) were shown. From baseline to follow-up, %OSPV reduced from 55.7 to 42.8%. VPI reduced from 61 to 56%. Coronary angiography was performed only at follow-up, showing yellow plaque and stent struts covered with thin transparent neointima (poor coverage) (c).
2.4. Statistical analyses

Categorical variables were presented as numbers and percentages. Continuous variables were presented as mean ± standard deviation. For categorical variables, we employed chi-square test. In comparison of continuous variables among three groups, we employed ANOVA. In comparison between the good coverage and poor coverage groups (Figs. 2 and 3), we employed unpaired $t$-test. Difference with $P < 0.05$ was considered significant. All statistical analysis was performed using SPSS software (SPSS, Chicago, IL).

3. Results

3.1. Patients and stented lesions

Thirty-nine G2-DES (9 BES, 15 EES, 15 R-ZES) were implanted into 37 patients. In coronary risk factors, dyslipidemia was significantly more frequent in patients implanted with the R-ZES group than those with BES and EES. Five of 7 patients of the BES group were patients with ACS (Table 1). Stent diameter of BES (3.4 ± 0.3 mm) was significantly greater than those of EES (3.0 ± 0.5 mm) and R-ZES (3.1 ± 0.4 mm, $P = 0.03$; see Table 2).

3.2. IVUS analyses

In gray-scale volumetric analysis (Fig. 1A-a and B-b), both OSPV and %OSPV reduced from baseline to follow-up only in EES (153.2 ± 93.4 to 145.8 ± 83.5 mm³, 38.2 ± 5.5 to 36.8 ± 4.5%, $P < 0.05$) but not in BES or R-ZES (Table 3). In iMAP tissue characterization analysis (Fig. 1A-a' and B-b'), necrotic fraction at baseline was the greatest in BES in comparison with EES and R-ZES (36.6 ± 5.6 vs. 32.9 ± 6.6 vs. 29.2 ± 5.1%, $P = 0.02$, see Table 4). Fibrotic faction at baseline was the lowest in BES in comparison with EES and R-ZES (50.1 ± 7.9 vs. 44.5 ± 11.8 vs. 40.9 ± 6.7%, $P = 0.04$), being compatible with prevalence of ACS in the BES patients (Table 3). There was no significant difference with regards to VPI at follow-up among the three G2-DES.

3.3. Coronary angioscopy at chronic phase

Coronary angioscopy revealed poor NSC in 67% of BES, 67% of EES, and 60% of R-ZES (Table 5). YP was observed most frequently in BES (56%) in comparison with EES (7%) and R-ZES (7%, $P = 0.004$). Although thrombus was detected only in one BES-implanted lesion, no statistical difference was found among three types of G2-DES ($P = 0.18$).

3.4. Impact of plaque burden on NSC

In BES, %OSPV at baseline was significantly greater in poor NSC than in good NSC (36.2 ± 3.9 vs. 27.3 ± 4.0%, $P = 0.01$, see Fig. 2). In EES, %OSPV was significantly greater in poor NSC than in good NSC (41.0 ± 4.1 vs. 32.6 ± 2.7%, $P < 0.01$). In R-ZES implantation, there was no significant difference with regards to %OSPV between poor and good NSC (36.4 ± 6.4 vs. 32.7 ± 3.5%, $P = 0.22$).

3.5. Impact of plaque vulnerability at acute phase on NSC

In BES, VPI at baseline was significantly greater in poor NSC than good NSC (54.0 ± 5.8 vs. 42.2 ± 5.1%, $P = 0.02$, see Fig. 3). There was no significant difference with regards to VPI between poor and good NSC in EES (46.0 ± 7.9 vs. 41.6 ± 8.5%, $P = 0.88$) and R-ZES (40.0 ± 7.4 vs. 42.1 ± 6.0%, $P = 0.57$).

Table 1

|                  | BES (n = 7) | EES (n = 15) | R-ZES (n = 15) | $P$-value |
|------------------|------------|--------------|----------------|-----------|
| Age, years       | 72.9 ± 7.1 | 67.4 ± 10.7  | 68.1 ± 8.6     | 0.33      |
| Gender, male (%) | 6 (86)     | 13 (87)      | 12 (80)        | 0.87      |
| Clinical diagnosis|           |              |                | 0.38      |
| ACS, (%)         | 5 (71)     | 7 (47)       | 6 (40)         |           |
| SAP, (%)         | 2 (29)     | 8 (53)       | 9 (60)         |           |
| Coronary risk factors |        |              |                |           |
| Hypertension, (%)| 7 (100)    | 13 (87)      | 12 (80)        | 0.44      |
| Dyslipidemia, (%)| 6 (86)     | 8 (53)       | 14 (93)        | 0.03      |
| Diabetes mellitus, (%) | 4 (57) | 5 (33) | 6 (40) | 0.57 |
| CKD, (%)         | 0 (0)      | 1 (7)        | 1 (7)          | 0.78      |
| Current smoker, (%) | 5 (71) | 11 (73) | 10 (67) | 0.92 |
| Medication†      |            |              |                |           |
| ACEI/ARB, (%)    | 5 (71)     | 7 (47)       | 10 (67)        | 0.42      |
| β-blocker, (%)   | 5 (71)     | 7 (47)       | 8 (53)         | 0.55      |
| Statin           | 6 (86)     | 7 (47)       | 11 (73)        | 0.14      |
| Dual ant-platelet therapy | 7 (100) | 14 (93) | 11 (73) | 0.14 |

Categorical data are expressed as percentage in 37 patients. Continuous variables are expressed as mean ± SD. †Medication at one-year after stenting. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Dual anti-platelet therapy, 100 mg aspirin plus 75 mg clopidogrel.
4. Discussion

In this study with iMAP-IVUS and coronary angiography, we first reported the relationship between out-stent plaque characteristics and arterial repair after implantation of three types of G2-DES. We found: 1) %OSPV decreased at one-year after EES implantation, whereas it increased after BES and R-ZES implantation; 2) the greater %OSPV immediately after BES and EES implantation was associated with the poor NSC at follow-up; 3) VPI at baseline was associated with the poor NSC at follow-up; 4) Neither %OSPV and VPI at baseline was associated with NSC at follow-up after R-ZES implantation. Impact of out-stent plaque characteristics on arterial repair at follow-up was stent-specific. A previous autopsy study argued that NSC after G1-DES (Sirolimus- or paclitaxel-eluting stent) implantation delayed at the vulnerable plaques, not at stable plaques [6], suggesting the impact of out-stent plaque vulnerability on arterial repair after stent implantation. A previous gray-scale IVUS study argued that reduction of out-stent plaque volume at chronic phase was associated with less in-stent intimal hyperplasia in patients with implantation of sirolimus-eluting stent or bare-metal stent [11]. A previous integrated backscatter-IVUS study clarified the difference between Taxus paclitaxel-eluting stent and Endeavor ZES with regards to out-stent plaque volume and vulnerability at chronic phase [12]. Recent angiographic studies revealed the different patterns of vascular response at chronic phase among different types of G2-DES [2,13]. In the present study, arterial repair after BES implantation was most affected by out-stent plaque characteristics. Arterial repair after EES was affected by out-stent plaque volume. Arterial repair after R-ZES implantation was not affected by out-stent plaque characteristics (Figs. 2 and 3).

Out-stent plaque volume regressed at follow-up after EES implantation (%OSPV 38.2 ± 5.5 to 36.8 ± 4.5, $P = 0.03$), whereas OSPV increased after BES and R-ZES implantation (Table 3). The reason for this phenomenon may be explained by EES specific performance. First, it is regarded that EES has anti-inflammatory and antithrombotic effect after stent placement [14–17], and these characteristic properties of EES may be related to reduction of underlying plaque volume. Second, it has been widely accepted that the aggressive lowering of LDL-cholesterol led to regression of coronary plaques [18]. In this study, morbidity of dyslipidemia in patients with EES implantation was significantly lower than in those with BES and R-ZES implantation (53% vs. 86 and 93%, respectively; $P = 0.03$). Rate of statin use was only 47% in patients with EES implantation, whereas it was significantly higher in those with BES and R-ZES implantation (93%).

In conclusion, impact of out-stent plaque characteristics on vascular response was different among BES, EES, and R-ZES.

Conflict of interest

The Authors declare that there is no conflict of interest.

Table 2
Lesion and stent characteristics.

|                | BES (n = 9) | EES (n = 15) | R-ZES (n = 15) | P-value |
|----------------|------------|-------------|----------------|---------|
| Follow-up period, days | 375.0 ± 32.3 | 350.8 ± 29.6 | 350.9 ± 27.4 | 0.61 |
| Stent diameter (mm) | 3.4 ± 0.3 | 3.0 ± 0.5 | 3.1 ± 0.4 | 0.03 |
| Total stent length (mm) | 300.0 ± 13.2 | 303.3 ± 13.4 | 275.2 ± 12.2 | 0.37 |
| Target vessel | LAD (%) | 3 (33) | 10 (67) | 14 (93) | 0.06 |
|                | LCX (%) | 1 (11) | 3 (20) | 2 (13) | 0.71 |
|                | RCA (%) | 5 (56) | 1 (7) | 0 (0) | 1 (7) | 0.25 |
| ACC/AHA lesion type | A/B1 (%) | 0 (0) | 1 (7) | 3 (20) | 0.12 |
|                | B2/C (%) | 9 (100) | 14 (93) | 12 (80) | |

Continuous variables are expressed as mean ± SD. Categorical data are expressed as numbers in 39 lesions. Continuous variables are expressed as mean ± SD. OSPV, out-stent plaque volume.

Table 4
iMAP-IVUS analyses.

|                | Phase | BES (n = 9) | EES (n = 15) | R-ZES (n = 15) | P-value |
|----------------|-------|------------|-------------|----------------|---------|
| Fibric (%) | Baseline | 40.7 ± 8.0 | 44.4 ± 6.5 | 48.7 ± 6.4 | 0.04 |
|                | Follow-up | 44.4 ± 6.5 | 48.3 ± 9.5 | 53.6 ± 7.1 | 0.90 |
| Lipidic (%) | Baseline | 13.7 ± 2.8 | 11.6 ± 2.13 | 11.7 ± 2.8 | 0.12 |
|                | Follow-up | 11.2 ± 2.0 | 10.1 ± 3.9 | 8.9 ± 1.9 | 0.09 |
| Necrotic (%) | Baseline | 36.6 ± 5.6 | 32.9 ± 6.6 | 29.2 ± 5.1 | 0.02 |
|                | Follow-up | 30.8 ± 6.5 | 28.9 ± 8.5 | 25.1 ± 6.2 | 0.12 |
| VPI (%) | Baseline | 50.1 ± 7.9 | 44.5 ± 11.8 | 40.9 ± 6.7 | 0.04 |
|                | Follow-up | 41.7 ± 7.7 | 38.7 ± 11.8 | 40.9 ± 6.7 | 0.08 |
| Calci (%) | Baseline | 2.4 ± 1.2 | 2.9 ± 1.4 | 3.2 ± 1.4 | 0.12 |
|                | Follow-up | 3.0 ± 1.4 | 4.2 ± 1.9 | 4.0 ± 2.7 | 0.33 |
| Ignored (%) | Baseline | 6.6 ± 1.3 | 8.1 ± 2.9 | 7.2 ± 1.9 | 0.28 |
|                | Follow-up | 7.2 ± 2.7 | 8.7 ± 3.1 | 7.6 ± 3.8 | 0.43 |

Continuous variables are expressed as mean ± SD. VPI, Vulnerable plaque index was defined as ratio of lipidic plus necrotic to total OSPV.
Table 5
Angioscopic comparison among 3 types of G2-DES.

| BES (n = 9) | EES (n = 15) | R-ZES (n = 15) | P-value |
|------------|-------------|---------------|---------|
| Poor NSC (%) | 6 (67) | 10 (67) | 9 (60) | 0.92 |
| Presence of YP (%) | 5 (56) | 1 (7) | 1 (7) | 0.004 |
| Presence of Th (%) | 1 (11) | 0 (0) | 0 (0) | 0.18 |

Acknowledgements

Authors thank Drs. Takashi Takagi, Mitsutoshi Asai, Yoshizumi Takei, and Tsuyoshi Nakata (Higashi-osaka City Medical Center) for their encouragement to pursue this study.

References

[1] M. Ichikawa, K. Bando, Y. Kijima, Angioscopic observation of extremely late arterial repair after intracoronary implantation of the first-generation sirolimus-eluting stents, Int. J. Cardiol. 230 (2017) 488–492.
[2] K. Kawai, M. Ichikawa, T. Masuyama, Y. Kijima, Angioscopic comparison of arterial repair after second-generation drug-eluting stent implantation into vulnerable and stable coronary plaques, Int. J. Cardiol. 221 (2016) 855–858.
[3] M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich, et al., Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk, J. Am. Coll. Cardiol. 48 (2006) 193–202.
[4] T. Higo, Y. Ueda, J. Oyabu, K. Okada, M. Nishio, A. Hirata, et al., Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study, JACC Cardiovasc. Imaging 2 (2009) 616–624.
[5] J. Kotani, M. Awata, S. Nanto, M. Uematsu, F. Oshima, H. Minamiguchi, et al., Incomplete neointimal coverage of sirolimus-eluting stents: angiographic findings, J. Am. Coll. Cardiol. 47 (2006) 2108–2111.
[6] G. Nakazawa, A.V. Finn, M. Joner, E. Ladich, R. Kutsy, E.K. Mont, et al., Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study, Circulation 118 (2008) 1138–1145.
[7] M. Utsunomiya, H. Hara, K. Sugi, M. Nakamura, Relationship between tissue characterisations with 40 MHz intravascular ultrasound imaging and slow flow during coronary intervention, EuroIntervention 7 (2011) 340–346.
[8] M. Ichikawa, Y. Takei, T. Hamasaaki, Y. Kijima, Characterization of patients with angiographically-detected in-stent mural thrombi - genetics of clopidogrel responsiveness and generations of drug-eluting stents, Circ. J. 79 (2015) 85–90.
[9] Y. Ueda, K. Matsuoi, M. Nishimoto, R. Sugihara, A. Hirata, T. Nemoto, et al., In-stent yellow plaque at 1 year after implantation is associated with future event of very late stent failure: the DESNOTE study (detect the event of very late stent failure from the drug-eluting stent not well covered by Neointima determined by Angioscopy), JACC Cardiovasc. Interv. 8 (2015) 814–821.
[10] M. Yamamoto, K. Okamatsu, S. Inami, M. Takano, S. Yokoyama, T. Obha, et al., Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy, Am. Heart J. 158 (1) (2009) 99–104.
[11] H. Tada, M.A. Kawashiri, K. Sakata, S. Takabatake, T. Tsubokawa, T. Konno, et al., Impact of out-stent plaque volume on in-stent intimal hyperplasia: results from serial volumetric analysis with high-gain intravascular ultrasound, Int. J. Cardiol. 158 (2012) 235–239.
[12] Y. Murakoa, S. Sonoda, K. Kashiyama, F. Kamezaki, Y. Tsuda, M. Araki, et al., Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation—comparison between zotarolimus-eluting stents and paclitaxel-eluting stents, Circ. J. 77 (2013) 363–371.
[13] Y. Nishimoto, Y. Ueda, R. Sugihara, A. Murakami, K. Ueno, Y. Takeda, et al., Comparison of angiographic findings among second-generation drug-eluting stents, J. Am. Coll. Cardiol. 70 (2017) 297–302.
[14] S. Verheye, W. Martinet, M.M. Kockx, M.W. Knaapen, K. Salu, J.P. Timmermans, et al., Selective clearance of macrophages in atherosclerotic plaques by autophagy, J. Am. Coll. Cardiol. 48 (2007) 706–715.
[15] Y. Muraoka, S. Sonoda, K. Kashiyama, F. Kamezaki, Y. Tsuda, M. Araki, et al., Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation: comparison between zotarolimus-eluting stents and paclitaxel-eluting stents, Circ. J. 77 (2013) 363–371.
[16] L. Pedrini, M. Dondi, A. Magagnoli, F. Magnoni, E. Pisano, E. Del Giudice, et al., Evaluation of thrombogenicity of fluoropassivated polyester patches following carotid endarterectomy, Ann. Vasc. Surg. 15 (2001) 679–683.
[17] T. Palmerini, G. Biondi-Zoccai, D. Della Riva, C. Stentieri, D. Sangiorgi, F. D’Ascenzo, et al., Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis, Lancet 379 (2012) 1393–1402.
[18] R. Puri, S.E. Nissen, R. Somaratne, L. Cho, J.J. Kastelein, C.M. Ballantyne, et al., Impact of PCSK9 inhibition on coronary atheroma progression: rationale and design of global assessment of plaque regression with a PCSK9 antibody as measured by intravascular ultrasound (GLAGOV), Am. Heart J. 176 (2016) 83–92.